Results 201 to 210 of about 153,345 (297)

High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.

open access: yesNew England Journal of Medicine, 1998
I. Martinelli   +5 more
semanticscholar   +1 more source

Variability in viscoelastic haemostatic assay in major haemorrhage protocols: A unified approach or mixed signals?

open access: yesTransfusion Medicine, EarlyView.
Abstract Background and Objectives Viscoelastic haemostatic assays (VHA) are part of patient blood management (PBM) for bleeding, associated with reduced transfusions. This study reviewed all major haemorrhage protocols (MHPs) using VHA in Queensland, Australia, and assessed variability.
Akmez Latona   +4 more
wiley   +1 more source

Recombinant protein expression in <i>Acanthamoeba castellanii</i>. [PDF]

open access: yesFront Bioeng Biotechnol
Salunke P, Kondabagil K, Karpe YA.
europepmc   +1 more source

Preparation and Properties of Prothrombin

open access: yesJournal of Biological Chemistry, 1959
Estelle Zonderman   +3 more
openaire   +3 more sources

Pitfalls in Argatroban Monitoring: Heparin Interference With Dilute Thrombin Time Assays

open access: yes
International Journal of Laboratory Hematology, EarlyView.
Agathe Herb   +3 more
wiley   +1 more source

Characterization and management of patients with hereditary factor X deficiency: A case series

open access: yesTransfusion, EarlyView.
Abstract Background Hereditary factor X deficiency (HFXD) is an ultra‐rare, autosomal recessive bleeding disorder that results in reduced factor X coagulant activity (FX:C). HFXD is traditionally classified by severity as severe (FX:C <1%), moderate (FX:C = 1%–5%), or mild (FX:C = 6%–10%).
Meera Chitlur   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy